Immunome Inc. (IMNM) News
Filter IMNM News Items
IMNM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest IMNM News From Around the Web
Below are the latest news stories about IMMUNOME INC that investors may wish to consider to help them evaluate IMNM as an investment opportunity.
Immunome to Present at the Stifel 2023 Healthcare ConferenceSEATTLE & EXTON, Pa., November 10, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET. |
Immunome Reports Third Quarter 2023 Financial ResultsSEATTLE & EXTON, Pa., November 09, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update. |
Immunome Appoints Jean-Jacques Bienaimé to Board of DirectorsSEATTLE & EXTON, Pa., November 08, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques "JJ" Bienaimé to its Board of Directors. Mr. Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals. |
7 Biotech Stocks to Get In Now Before Investors Catch OnBiotech stocks are down, but there are hidden gems among the rubble. |
Immunome Appoints Bob Lechleider, M.D., as Chief Medical OfficerSEATTLE & EXTON, Pa., October 19, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer. Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research. |
Insider Buying: Immunome Inc's President and CEO Clay Siegall Acquires 169,204 SharesOn October 2, 2023, Clay Siegall, the President and CEO of Immunome Inc (NASDAQ:IMNM), made a significant insider purchase of 169,204 shares of the company. |
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer TherapiesSEATTLE & EXTON, Pa., October 03, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it has completed its previously announced merger with Morphimmune. |
Individual investors who hold 51% of Immunome, Inc. (NASDAQ:IMNM) gained 15%, institutions profited as wellKey Insights Immunome's significant individual investors ownership suggests that the key decisions are influenced by... |
Inside the deal: How Immunome and MophImmune came to a merger agreementA fortuitous chain of events led to a merger and a $125 million PIPE financing deal, both of which are expected to be completed next month. |
Immunome Reports Second Quarter 2023 Financial ResultsEXTON, Pa., August 09, 2023--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. |